



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



Studio del ruolo del long non-coding RNA BALR-2 nella leucemia mieloide acuta

Bisio Valeria, PhD

**Tregnago C, Borella G, Benetton M, Zanon C, Santoro N, Pierani P, Micalizzi C,
Locatelli F, Basso G, Pigazzi M.**

V Workshop AIEOP in LAB – 28-29 Maggio 2018 - Bologna

Long non coding RNA







Fig. 1 lncRNAs in acute myeloid leukemia. lncRNAs influence apoptosis, differentiation and proliferation of acute myeloid leukemia cells.

Long non coding RNA-BALR-2 nelle LAM

Rao et al. Molecular Cancer Cell 2015

Pazienti: 132 LAM *de novo* AIEOP 2002/01




BALR-2 Exp
segue BULK
leucemico


Espressione di BALR-2 nelle LAM

Analisi supervisionata su 85 pazienti LAM *de novo* con diverse aberrazioni genetiche tramite Array HTA 2.0


Quartile BALR-2




Coding



Aberration




Non coding




57 geni codificanti e 12 geni non codificanti differenzialmente espresse tra 18 e 40 pazienti con LAM *de novo* con alta con bassa espressione di BALR-2, rispettivamente.
(p-value<0.01, FC>|2|).

Localizzazione cromosomica



LncRNA = REGOLATORI DI ESP LOCALI



BALR-2/CDK6 bidirectional promoter



Carlo Zanon

Asse BALR-2 /CDK6




Nei pazienti




Ruolo di BALR-2 nelle LAM pediatriche

Asse BALR-2 /CDK6

In vitro




Ruolo di BALR-2 nelle LAM pediatriche



Ruolo di BALR-2 nelle LAM pediatriche




Geni target di RUNX1 e coinvolti nel differenziamento mieloide nei pazienti



Ruolo di BALR-2 nelle LAM pediatriche

Silencing BALR2


In vitro



Alta espressione di BALR-2 e CDK6


- Quartile 1
- Quartile 2
- Quartile 3
- Quartile 4

- t(8;21)
- DEK-NUP214
- FLT3-ITD
- inv(16)
- MLL-t
- Negative
- NUP98-t



single-sample GSEA


Ruolo di BALR-2 nelle LAM pediatriche



- Stadi differenziativi della cellula
- Resistenza alla terapia

Ruolo di BALR-2 nelle LAM pediatriche

Morfologia mitocondriale





I livelli di BALR-2 modulano la massa mitocondriale

Ruolo di BALR-2 nelle LAM pediatriche

Funzionalità mitocondriale




ATTIVITA' DEI COMPLESSI RESPIRATORI



Alti livelli di BALR-2 inducono un aumentata attività del COMPLESSO IV (citocromo c ossidasi) della catena respiratoria

Ruolo di BALR-2 nelle LAM pediatriche



Funzionalità mitocondriale



Differente risposta agli inibitori mitocondriali in base ai livelli di BALR-2

Ruolo di BALR-2 nelle LAM pediatriche




Funzionalità mitocondriale




I livelli di BALR-2 modulano la produzione di ATP

Ruolo di BALR-2 nelle LAM pediatriche

Risposta terapeutica



Conclusioni



PROSPETTIVE FUTURE

- Approfondire il ruolo dei mitocondri nella LAM resistenza alla terapia ↔ inibitori mitocondriali come nuova strategia terapeutica
- Produrre virus sh-BALR2: silenziamento stabile in CD34+ per validare se BALR-2 è cruciale nel blocco del differenziamento tipico della leucemia

Ringraziamenti



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



PI: Dr. Martina Pigazzi

Dr. Claudia Tregnago

Dr. Matteo Zampini

Giulia Borella PhD student

Maddalena Benetton PhD student

Ambra dal Ros PhD student

Katia Polato tecnico

Laboratorio di Oncoematologia

Dipartimento di Salute della Donna e del Bambino-

Università degli Studi di Padova

Direttore Prof. G Basso

Genetica Medica

Dr. Eva Trevisson

Dr. Cristina Cerqua

Facility di Bioinformatica IRP:

Carlo Zanon

AML working group

Coordinator: Prof. Franco Locatelli

Prof. Andrea Pession

Riccardo Masetti

Pietro Merli

Carmelo Rizzari

Roberto Rondelli

Franca Fagioli

Maria Caterina Putti

Concetta Micalizzi

Marco Zecca

Angela Mastronuzzi

Annamaria Testi

Giuseppe Menna

Nicola Santoro

Paolo Pierani

Luca Lonigro



Fondazione
**ISTITUTO DI RICERCA
PEDIATRICA**



Progetto sostenuto dalla

Fondazione
Cassa di Risparmio di Padova e Rovigo







Prof. Silvia Campello

Dr. Luca Simula

Dr. Matteo Borghi

	BALR-2 exp		
	I+II+III quartile	IV quartile	p-value
TOTAL	100 (75%)	32 (24.2%)	
Sex			ns
F	38 (38%)	21 (65.5%)	
M	62 (62%)	11 (34.4%)	
age			0,006
<2 yrs	27 (27%)	1 (3%)	
2-10 yrs	36 (36%)	11 (34%)	
>10 yrs	37 (37%)	20 (62.5%)	
mean	7,4	10,1	
WBC count (x10⁹/L)			ns
<10	29 (29%)	7 (21.8%)	
>10<99	47 (47%)	14 (43.7%)	
>100	16 (16%)	9 (28.1%)	
N/A	8 (8%)	2 (6.2%)	
mean	49447	101279	
FAB			ns
M0	10 (10%)	3 (9.3%)	
M1	11 (11%)	8 (25%)	
M2	17 (17%)	7 (21.8%)	
M4	13 (13%)	4 (12.5)	
M5	27 (27%)	5 (15.6)	
M6	1 (1%)	0 (0%)	
M7	4 (4%)	3 (9.3%)	
N/A	17 (17%)	2 (6.2%)	
Molecular Marker			ns
CBF-rearranged	13 (13 %)	7 (21.8%)	
FLT3-ITD	11 (11%)	4 (12.5)	
NUP98-t	9 (9%)	6 (18,7)	
MLL-t	33 (33%)	4 (12.5)	
Rare translocations	8 (8%)	1 (3,1%)	
No Molecular Marker	26 (26%)	10 (31,2)	
Karyotype			ns
Complex	8 (8%)	4 (12.5%)	
Monosomal	2 (2%)	1 (3.1%)	
Normal	65 (65%)	21 (65.6%)	
N/A	25 (25%)	6 (18.7)	
Primary Induction Failure (PIF)			ns
YES	8 (25%)	5 (15.6%)	
NO	92 (92%)	27 (13.5)	
Remission			0,03
YES	88 (88%)	23 (71.8%)	
NO	12 (12%)	9 (28.1%)	
Relapse			ns
YES	25 (25%)	9 (28.1%)	
NO	75 (75%)	23 (71.8%)	





Aberration

- t(8;21)
- DEK-NUP214
- FLT3-ITD
- inv(16)
- MLL-t
- Negative
- NUP98-t

Quartile BALR-2

- Quartile 1
- Quartile 2
- Quartile 3
- Quartile 4

ssGSEA Score

Row min Row max

MITOCHONDRIAL_ENVELOPE *

MITOCHONDRIAL_MEMBRANE *

MITOCHONDRION *

GO_MITOCHONDRIAL_TRANSLATION **

